OOIR: Observatory of International Research

Papers

(The H4-Index of Rheumatology is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Activation of circulating monocytes by low-density lipoprotein—a risk factor for osteoarthritis?	127
Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists: reply	93
Boxer’s shape, an unusual finding in nailfold capillaroscopy	85
Will we ever agree on using low-dose glucocorticoids in treating rheumatoid arthritis?	66
Clinical and serological resolution of pembrolizumab associated Sjögren’s syndrome: long-term follow-up	63
Editor’s Acknowledgement	63
Comment on: ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies	61
Bullous periorbital oedema in anti-p155/140-positive dermatomyositis: a case series	56
Comment on: Increased risk of osteoporosis and femoral neck fractures in patients with familial Mediterranean fever—a large retrospective cohort study	55
Genetics of longitudinal kidney function in children and adults with systemic lupus erythematosus	54
Comment on: Persistence of circulating T-follicular helper cells after rituximab is associated with relapse of IgG4-related disease	50
Comment on: Switching from prednisolone to dexamethasone in difficult-to-treat rheumatoid arthritis	49
Corrigendum to: Patient and Rheumatologist Perspectives on Tapering DMARDs in Rheumatoid Arthritis: A Qualitative Study	48
COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study	48
Haematologic malignancy-associated mucocutaneous paraneoplastic syndrome	47
Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis—caution is key in interpreting retrospective data: Reply	47
The influence of biological DMARDs on aseptic arthroplasty loosening: a retrospective cohort study	47
The role of IL-23 in joint disease	45
Comment on: Muscle involvement in systemic lupus erythematosus: multimodal ultrasound assessment and relationship with physical performance	45
Annular erythematous plaques as manifestation of vasculitis in pediatric Sjögren’s syndrome	43
Prosthetic infections following tocilizumab treatment in patients with rheumatoid arthritis	43
Comment on: The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis: reply	43
Granulomatosis with polyangiitis presenting as obstructive uropathy and vasculitic myopathy	43
A case of carpal tunnel syndrome caused by gouty tophi confirmed by dual-source CT	43
Correction to: Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis	41

Validation of a questionnaire for central nervous system aspects of joint pain: the CAP questionnaire	41
Clinico–pathological phenotypes of systemic sclerosis–associated myopathy: analysis of a large multicentre cohort	41
Biopsy vs imaging for the diagnosis of giant cell arteritis. Viewpoint 2: in favour of biopsy	40
Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment	39
Combined radiographic and US evaluations to decipher joint involvement in the hands of patients with SSc	39
Factors associated with delay in the diagnosis and treatment of systemic lupus erythematosus in adult patients: a systematic review	39
Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study	39
Central retinal vein and cilioretinal artery occlusion in a case of systemic sclerosis treated with a JAK inhibitor figlotinib	38
A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis	38
Identification of circulating microRNA patterns in patients in psoriasis and psoriatic arthritis	37
Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE	37
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients	36
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs	36
Transient osteoporosis of the hip: a novel vascular manifestation of COVID-19?	36